Shire bails out of Baxalta biosimilars, ends Coherus, Momenta deals – FierceBiotech


FierceBiotech

Shire bails out of Baxalta biosimilars, ends Coherus, Momenta deals
FierceBiotech
It’s been almost three months since the Shire-Baxalta deal closed in early June. As part of that vision, Shire committed to double-digit, top-line revenue growth with total revenue to exceed $20 billion by 2020. At the Baxalta transaction close, 65% of

and more »

Read More…

Share This: